Gleb Kuznetsov is co-founder and CEO of Manifold Bio, a biotechnology company aiming to revolutionize protein therapeutics discovery through novel measurement and design technologies. The company was co-founded with Gleb’s PhD advisor George Church and is focused on creating targeting-enhanced protein therapeutics leveraging its in vivo biologics design platform powered by a novel protein barcoding technology. Gleb comes from an interdisciplinary technical background spanning computational and molecular biology. He completed a Ph.D. in the Harvard Biophysics program combining massively parallel capabilities of DNA sequencing, DNA synthesis, and machine learning technologies to engineer biological systems from the protein to the genome scale.